Curis (NASDAQ:CRIS) Stock, Quote.Headers.trade-ideas

Curis

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

News

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CRIS

RVMD

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q2

Price Target

Analyst Ratings

CYBR

LBTYA

NOTV

PCTY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday

Small Cap

Intraday Update

Movers

ANVS

DWAC

ENSC

EVAX

EVER

GETR

GPAK

GYRE

HRTX

KURA

LCID

MMAT

NFLX

NYXH

PRPL

RDHL

RVSN

SAVE

SBEV

SIDU

SMMT

SPRC

SRAD

SWIN

VSME

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes.

BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Curis Inc

CRISPR THERAPEUTICS ORD

CRISPR Therapeutics AG

CRISM THERAPEUTICS CORP by CRISM THERAPEUTICS CORP

Crism Therapeutics Corp

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.67) by 21.56 percent. This is a 17.81 percent increase over losses of $(2.47) per share from the same period last year. The company reported quarterly sales of $2.546 million which beat the analyst consensus estimate of $2.064 million by 23.37 percent. This is a 15.89 percent increase over sales of $2.197 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Curis Q2 2024 GAAP EPS $(2.03) Misses $(1.67) Estimate, Sales $2.546M Beat $2.064M Estimate

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNSP

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Truist Securities analyst Robyn Karnauskas maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Truist Securities Maintains Buy on Curis, Maintains $26 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Curis

Data update expands AML dataset from 5 to 30 patients
LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Prior
Data
</td>
<td colspan="2" rowspan="1">New Data&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FLT3m AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">12</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SFm AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">adjustment for patients with dual mutation&#x2A;&#x2A;</td>
<td colspan="2" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">5</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;&nbsp; data cut-off as of February 26, 2024 &#x2A;&#x2A;&nbsp; 2 patients had both FLT3m and SFm (dual mutation) &nbsp; &nbsp; 1 patient in the initial group of 5 patients; 1 patient in the new group of 25 additional patients

Biotech

General

Curis To Present Updated Data From TakeAim Leukemia Study  At The ASCO And EHA Conferences

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.05) per share which beat the analyst consensus estimate of $(2.12) by 3.3 percent. This is a 14.58 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $2.09 million which missed the analyst consensus estimate of $2.40 million by 13.08 percent. This is a 9.19 percent decrease over sales of $2.30 million the same period last year.

Curis Q1 EPS $(2.05) Beats $(2.12) Estimate, Sales $2.09M Miss $2.40M Estimate

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>OncoCyte Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>)</h3>
<ul>
<li>On April 11, Oncocyte announced a $15.8 million private placement of securities priced at-the-market under Nasdaq rules. The company&rsquo;s stock gained around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/OCX">52-week high of $6.80 </a>.</li>
<li>RSI Value: 73.87</li>
<li>OCX Price Action: Shares of OncoCyte rose 1.2% to close at $2.9650 on Thursday.</li>
</ul>
<h3>Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>)</h3>
<ul>
<li>On April 5, Curis reported inducement grants under NASDAQ Listing Rule 5635(c)(4). The company&rsquo;s stock gained around 59% over the past month and <a href="https://www.benzinga.com/quote/CRIS"> has a 52-week high </a> of $17.49.</li>
<li>RSI Value: 75.26</li>
<li>CRIS Price Action: Shares of Curis gained 4.1% to close at $15.90 on Thursday.</li>
</ul>
<h3>Revolution Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvmd#NASDAQ">RVMD</a>)</h3>
<ul>
<li>On April 9, the company announced the publication of a research paper on RMC-6236 in Cancer Discovery. The company&rsquo;s stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/RVMD"> 52-week high </a> of $38.73.</li>
<li>RSI Value: 72.27</li>
<li>RVMD Price Action: Shares of Revolution Medicines gained 2.5% to close at $37.41 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38215617/fear-greed-index-moves-to-greed-zone-following-ppi-data-nasdaq-record-sharp-gains"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone Following PPI Data; Nasdaq record Sharp Gains </a>

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares moved upwards by 24.62% to $16.7. The market value of their outstanding shares is at $98.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock declined by 80.2% to $3.25 during Thursday's regular session. The company's market cap stands at $11.9 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) stock decreased by 24.17% to $0.91. The market value of their outstanding shares is at $37.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares fell 16.81% to $7.87. The company's market cap stands at $202.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 14.55% to $2.35. The company's market cap stands at $8.5 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares declined by 13.48% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock declined by 12.85% to $2.51. The market value of their outstanding shares is at $48.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

BRNS

CADL

CTCX

EFTR

EIGR

Kintara Therapeutics, Inc. - Common Stock

KTRA

MGNX

TCBP

12 Health Care Stocks Moving In Thursday's Intraday Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rl#NYSE">RL</a>) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Ralph Lauren shares jumped 16.8% to close at $171.85 on Thursday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC cut Bunge Global SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bg#NYSE">BG</a>) price target from $122 to $105. HSBC analyst Wesley Brooks upgraded the stock from Hold to Buy. Bunge Global shares fell 1.7% to close at $86.50 on Thursday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies boosted the price target for Inotiv, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/notv#NASDAQ">NOTV</a>) from $3 to $11.5. Jefferies analyst David Windley upgraded the stock from Hold to Buy. Inotiv shares gained 16.8% to close at $4.30 on Thursday. <a href="https://www.benzinga.com/quote/NOTV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Everest Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eg#NASDAQ">EG</a>) price target from $484 to $402. Wells Fargo analyst Elyse Greenspan downgraded the stock from Overweight to Equal-Weight. Everest Group shares fell 7.7% to close at $354.56 on Thursday. <a href="https://www.benzinga.com/quote/EG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted the price target for Spectrum Brands Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spb#NYSE">SPB</a>) from $83 to $86. Canaccord Genuity analyst Brian McNamara downgraded the stock from Buy to Hold. Spectrum Brands shares rose 7.7% to close at $86.10 on Thursday. <a href="https://www.benzinga.com/quote/SPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup cut the price target for Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) from $175 to $120. Citigroup analyst Patrick Cunningham downgraded the stock from Buy to Neutral. Albemarle shares fell 0.6% to close at $114.33 on Thursday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased CyberArk Software Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cybr#NASDAQ">CYBR</a>) price target from $245 to $310. Needham analyst Alex Henderson maintained a Buy rating. CyberArk Software shares gained 7.6% to close at $261.60 on Thursday. <a href="https://www.benzinga.com/quote/CYBR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler boosted Paylocity Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcty#NASDAQ">PCTY</a>) price target from $207 to $210. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Paylocity Holding shares gained 2.1% to close at $171.91 on Thursday. <a href="https://www.benzinga.com/quote/PCTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>) price target from $51 to $26. HC Wainwright &amp; Co. analyst Edward White maintained a Buy rating. Curis shares rose 13.4% to close at $10.65 on Thursday. <a href="https://www.benzinga.com/quote/CRIS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup boosted Liberty Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbtya#NASDAQ">LBTYA</a>) price target from $20 to $24. Citigroup analyst Nayab Amjad upgraded the stock from Neutral to Buy. Liberty Global shares fell 1.1% to close at $19.06 on Thursday. <a href="https://www.benzinga.com/quote/LBTYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37030079/dbv-technologies-and-2-other-stocks-under-2-insiders-are-buying"> DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying </a>

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $51 to $26.

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26

Offerings

Curis Said May Offer, Sell Shares Of Common Stock From Time To Time In One Or More Offerings Of Up To $300M In Aggregate Offering Price

Guidance

Health Care

As Of December 31, 2023, Curis's Cash, Cash Equivalents And Investments Totaled $56.3M. Curis Expects Its Existing Cash, Cash Equivalents And Investments Should Enable Its Planned Operations Into 2025

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which beat the analyst consensus estimate of $(2.11) by 3.79 percent. This is a 13.62 percent increase over losses of $(2.35) per share from the same period last year. The company reported quarterly sales of $2.70 million which missed the analyst consensus estimate of $3.02 million by 10.73 percent. This is a 6.62 percent decrease over sales of $2.89 million the same period last year.

Curis Q4 EPS $(2.03) Beats $(2.11) Estimate, Sales $2.70M Miss $3.02M Estimate

AFRM

AIRC

APDN

ARES

AXTA

BILL

BIOX

CIGI

CIVB

CLSK

CPRI

CTLP

CTRE

DOCS

DXCM

EGAN

EMKR

EXPE

FARM

FLUX

FORR

GTES

IBEX

IIIV

ILMN

IRMD

JRSH

KVUE

LADR

LITE

LIVE

LPTH

LQDT

LSPD

LTRX

LVWR

NGVC

OMCL

ONTO

PATK

PEAK

PECO

PETS

PINE

PINS

PODC

Earnings Scheduled For February 8, 2024

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-08. Here's what investors need to know before the announcement.
Analysts estimate that Curis will report an earnings per share (EPS) of $-2.11. 
Curis bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.20, which was followed by a 1.33% increase in the share price the next day.
Here's a look at Curis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.33</td>
<td>-2.4</td>
<td>-2</td>
<td>-0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.13</td>
<td>-2.4</td>
<td>-2.4</td>
<td>-2.40</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.33%</td>
<td>-8.82%</td>
<td>-3.96%</td>
<td>-2.73%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707336103_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Curis were trading at $9.42 as of February 06. Over the last 52-week period, shares are down 34.57%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRIS/earnings">To track all earnings releases for Curis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Curis's Earnings: A Preview

Shares of BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) fell sharply during Wednesday&rsquo;s session after the company announced a proposed private offering of $160 million of convertible senior notes.
BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Getaround, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/getr#NYSE">GETR</a>) shares jumped 151.3% to $0.4618 after the company announced a new debt facility with Mudrick Capital Management for up to $20 million.</li>
<li>Evaxion Biotech A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evax#NASDAQ">EVAX</a>) gained 94.4% to $9.70 after a 13G filing showed Merck &amp; Co reported an 11.4% stake in the company as of Dec. 21, 2023.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares gained 61.3% to $5.58 after the company revealed $20 million standby equity purchase agreement.</li>
<li>Kura Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kura#NASDAQ">KURA</a>) rose 41.3% to $18.99. Kura Oncology announced oversubscribed $150 million private placement.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensc#NASDAQ">ENSC</a>) shares jumped 32.2% to $1.8372. Ensysce Biosciences shares gained 22% on Tuesday after the company announced FDA Breakthrough Therapy Designation for PF614-MPAR.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) climbed 25.5% to $1.1197. Redhill Biopharma was granted U.S. Patent #11878011 for &quot;Method for Eradicating Helicobacter Pylori Infection in Patients Regardless of Body Mass Index.&quot;</li>
<li>Purple Innovation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prpl#NASDAQ">PRPL</a>) gained 24% to $1.02 after the company announced it strengthened its balance sheet, creating greater financial flexibility to execute its growth strategy. The company also reaffirmed 2023 guidance.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) rose 23% to $1.56. Nxu recently filed for offering of up to 1 million Class A common shares by the selling stockholder.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) rose 23% to $9.76.</li>
<li>Solowin Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swin#NASDAQ">SWIN</a>) gained 20% to $4.0001.</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) surged 16.3% to $6.51 after surging over 20% on Tuesday.</li>
<li>Heron Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>) gained 15.6% to $2.5450. Heron Therapeutics received FDA approval of ZYNRELEF&reg; indication expansion to include additional orthopedic and soft tissue procedures.</li>
<li>Netflix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) shares climbed 12.6% to $554.00 as the company reported better-than-expected sales for its fourth quarter.</li>
<li>VS MEDIA Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsme#NASDAQ">VSME</a>) shares gained 10.5% to $0.3626 after gaining around 3% on Tuesday.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) rose 10.5% to $4.5208.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) gained 10% to $12.98.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) shares climbed 9% to $11.87.</li>
<li>SAP SE (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sap#NYSE">SAP</a>) gained 6.8% to $174.64 after the company reported fourth-quarter financial results.</li>
<li>Textron Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/txt#NYSE">TXT</a>) rose 6% to $ 84.09 following upbeat quarterly earnings.</li>
<li>The Progressive Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgr#NYSE">PGR</a>) gained 5.4% to $179.49 after the company reported fourth-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rr#NASDAQ">RR</a>) shares dipped 31.3% to $7.62.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) fell 26.7% to $4.8701. Foresight Autonomous, said its affiliate, Rail Vision received order from leading U.S.-Based rail contractor of up to $5m for the purchase of Rail Vision&#39;s artificial intelligence-based Switch Yard Systems.</li>
<li>Gamer Pakistan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpak#NASDAQ">GPAK</a>) declined 20.4% to $0.2708.</li>
<li>Splash Beverage Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbev#NYSE">SBEV</a>) fell 20% to $0.3804.</li>
<li>Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>) fell 18.7% to $9.20.</li>
<li>Annovis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anvs#NASDAQ">ANVS</a>) fell 16.9% to $9.67 after the company announced a postponement in the Phase III study data release for buntanetap in Parkinson&#39;s Disease.</li>
<li>DuPont de Nemours, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dd#NYSE">DD</a>) fell 12.8% to $65.14 after the company announced preliminary fourth-quarter and full year 2023 results, and issued first-quarter guidance.</li>
<li>Sportradar Group AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srad#NASDAQ">SRAD</a>) declined 11% to $10.25. Sportradar Chief Financial Officer Gerard Griffin has informed that he will be leaving for personal reasons. However, Griffin will continue as CFO until May 31, 2024.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) fell 9.4% to $14.64.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 9.3% to $7.38.</li>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares dipped 8.3% to $0.0612. Meta Materials announced a 1-for-100 reverse stock split to regain Nasdaq compliance.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) shares fell 7.4% to $46.93. Digital World has an agreement in place to merge with Trump Media and Technology Group, which owns the Truth Social platform, to bring the latter public.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) fell 7.3% to $2.81.</li>
<li>Diversified Energy Company PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dec#NYSE">DEC</a>) fell 7% to $12.00.</li>
<li>Texas Instruments Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>) shares fell 2.4% to $170.20 after the company reported fourth-quarter financial results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36759069/bitcoin-surpasses-40-000-manta-network-emerges-as-top-gainer"> Bitcoin Surpasses $40,000; Manta Network Emerges As Top Gainer </a>

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock rose 48.1% to $19.87 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock increased by 34.87% to $0.42. The market value of their outstanding shares is at $12.5 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 25.87% to $1.75. The company's market cap stands at $5.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 21.86% to $2.62. The market value of their outstanding shares is at $16.1 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 21.4% to $1.08. The market value of their outstanding shares is at $21.2 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares rose 20.5% to $4.29. The market value of their outstanding shares is at $6.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) stock fell 19.2% to $9.4 during Wednesday's regular session. The company's market cap stands at $96.4 million. </li>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) shares fell 18.99% to $4.31. The market value of their outstanding shares is at $210.1 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock declined by 14.98% to $13.74. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares fell 14.98% to $9.62. The company's market cap stands at $56.7 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 13.32% to $3.24. The market value of their outstanding shares is at $31.1 million. </li>
<li>PetVivo Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETV#NASDAQ">PETV</a>) stock decreased by 12.68% to $1.17. The company's market cap stands at $16.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CING

ELTX

PETV

SGHT

TBIO

12 Health Care Stocks Moving In Wednesday's Intraday Session

Curis Inc (CRIS) has issued an announcement. Curis, Inc. has revealed promising updated data from its TakeAim Leukemia study, which will be showcas...

Curis Inc Showcases Leukemia Study Breakthroughs at Conferences

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Curis (CRIS – Research Report), Health Catalyst (HCAT – Research ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)

Edward White, an analyst from H.C. Wainwright, maintained the Buy rating on Curis (CRIS – Research Report). The associated price target remains the...

Buy Rating Affirmed for Curis's Emavusertib Following Promising Leukemia Study Results

Curis (CRIS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading m...

Buy Rating Affirmed on Curis's Emavusertib for Its Potential to Overcome Drug Resistance in AML and MDS

Notable earnings before Thursday's open

Curis Q2 2024 Earnings Preview

Curis GAAP EPS of -$2.03 misses by $0.35, revenue of $2.5M beats by $0.44M

Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Curis (CRIS – Research Report). The company's sha...

Truist Financial Reaffirms Their Buy Rating on Curis (CRIS)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Curis (CRIS – Research Report) today. The company's shares closed yesterda...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Curis

Curis (CRIS) Forecast

Curis (NASDAQ:CRIS) Stock, Quote.Headers.trade-ideas